ERBB2 and breast cancer: Fribbes, C. et al. conducted a prospective–retrospective analysis, assessing ESR1 mutations in available archived plasma from the Study of Faslodex vs. Exemestane with or without Anastrozole (SoFEA) and Palbociclib Combined with Fulvestrant in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer after Endocrine Failure (PALOMA3) trials.